August #73 : Playing for Time - by Tim Murphy

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Gimme A Break!

Too Close for Comfort

On an Off Trial

Publisher's Letter

Mailbox

Got Asylum?

Dogma Doo

Bad Ad Fad

Highest Court On Weed

Obit: Robert C. Randall

The Tour de France

Center Stage

Drama Queens

Lipo Ladies

Her So Good

Playing for Time

Herb Blurb

Hurry Up, PEP, It’s Time!

Is Less More in Safe-Sex Ed?

Combo Condom

Pregger Rap

Pocket Money

Good Company

20 Years And Counting

Missing in Action

Memo From Hell

Material Girl

Snap Shots: Joe Westmoreland



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

August 2001

Playing for Time

by Tim Murphy

The promising new anti-HIV drug tenofovir DF (disoproxil fumarate) is ready for its FDA close-up. But has its maker kept HIVers who need it from getting up close?

California biotech Gilead Sciences was beaming last February when it released findings from its Phase III tenofovir trial. The upshot: In a study of some 550 HIVers with an average five-year history of HAART, viral load (originally between 400 and 10,000 copies) fell by an average of 75 percent by 24 weeks after the new drug was added to their regimen. Viral load also dropped below the “cutting edge” undetectable marker of 40 copies for 22 percent and the “old school” marker of 400 for 45 percent.

Such impressive results recommend tenofovir as a lead player in the most urgent treatment drama—combating the resistance that many pre-protease pill-poppers have to current cocktails. Plus, Gilead’s new offering has demonstrated no major side effects—good news in light of the nasty kidney kinks that made the FDA nix Gilead’s earlier adefovir.    

Fast-forward to May 2001, when Gilead submitted tenofovir to the FDA for approval under its fast-track AIDS-drug program, which has a six-month-max review. All signs indicate smooth sailing for the drug, which is due to hit the market right before or just after the new year.

When it does, tenofovir (no brand name yet) will be the first in a new class of anti-HIV drugs called nucleotide analogs—not to be confused with the nucleosides, or NRTIs, such as AZT—that prevent HIV from entering the nucleus of healthy CD4s and producing new virus. It will have to be taken in a cocktail with an NRTI and at least one protease inhibitor or NNRTI.

Precisely because tenofovir is such a bright 11th-hour hope for HIVers facing treatment failure due to resistance, Gilead started an expanded-access program (in which pre-approval drugs are made available for free in emergency situations) last February—but one with Byzantine restrictions: patients had to have a viral load over 10,000 and a CD4 count under 100, unless their CD4s were up to 200, in which case they had to have had an AIDS-defining illness in the past 90 days, or to have failed on a two-PI or a PI/NNRTI combo. All this was very different from tenofovir expanded access in Europe, where a failing regimen was qualification enough.

Soon, Gilead’s program came under fire from the Coalition for Salvage Therapy (CST), an ad hoc group of treatment activists founded in 1998. CST sent a letter accusing the biotech of deliberately limiting and slowing enrollment—to save money on drug giveaways. In response to Gilead’s official explanation that processing paperwork was time consuming, the CST missive clarified exactly what is at stake: the lives of “patients with few or no remaining options for treatment…[and those] whose disease has been allowed to progress to the point where ‘waiting for things to get sorted out’ with the program is simply not an option.”

Stung by bad publicity, Gilead dropped all requirements for the program except “for adults whose physicians feel they need a viable treatment regimen,” according to Gilead rep Amy Flood, who says that the program has been “steadily ramping up” to about 1,000 people. “We’ve worked closely with our CRO [contract research organization, which arranges such programs for pharmaceuticals] to make sure there are no steps that are a time hang-up,” she says. “We have an ongoing dialogue with CST and are open to feedback.”

The question of who got early tenofovir will be overshadowed when it wins FDA OK. But advocates call the flap a sad commentary on the current availability of investigative drugs for HIVers for whom the difference between life and death can be a vexing game of time.  




[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    aqua_31206
    Macon
    Georgia


    juliar33
    brooklyn
    New York


    Fred9774
    Brooklyn
    New York


    donnyp
    liberty
    Kentucky
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you work with your doc to design your own treatment regimen?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.